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Synergistic effects of TNF-a and melphalan in an isolated limb perfusion 
model of rat sarcoma: a histopathological, immunohistochemical and 
electron microscopical study
PTGA Nooijen', ER Manusama2, AMM Eggermont2, L Schalkwijk1, J Stavast2, RL Marquet2, 
RMW de Waal1 and DJ Ruiter'
'Department of Pathology, University Hospital Nijmegen, Nijmegen, The Netherlands;2 Department of Surgery, University Hospital 
Rotterdam, Dr. Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
Summary Isolated limb perfusion (ILF) with tumour necrosis factor alpha (TNF-a) and melphalan has shown 
impressive results in patients with irresectable soft tissue sarcomas and stage III melanoma of the extremities. 
The mechanisms of the reported in vivo synergistic anti-tumour effects of TNF-a and melphalan are not 
precisely understood. We have developed an I LP model in the rat using a non-immunogenic sarcoma in which 
similar in vivo synergy is observed. The aim of this present study was to analyse the morphological substrate for 
this synergistic response of TNF-a in combination with melphalan to shed more light on the pathomechanisms 
involved. Histology of the tumours from saline- (n~ 14) and melphalan-treated («== 11) rats revealed apparently 
vital tumour cells in over 80% of the cross-sections. Interstitial oedema and coagulation necrosis were observed 
in the remaining part of the tumour. Haemorrhage was virtually absent. TNF-a (« = 22) induced marked 
oedema, hyperaemia, vascular congestion, extravasation of erythrocytes and haemorrhagic necrosis (20~ 60% 
of the cross-sections). Oedema and haemorrhage suggested drastic alterations of permeability and integrity of 
the microvasculature. Using light and electron-microscopy, we observed that haemorrhage preceded generalised 
platelet aggregation. Therefore, we suggest that the observed platelet aggregation was the result of the 
microvascular damage rather than its initiator. Remarkably, these events hardly influenced tumour growth. 
However, perfusion with the combination of TNF-a and melphalan (n = 24) showed more extensive 
haemorrhagic necrosis (80-90% of the cross-sections) and revealed a prolonged remission (mean 11 days) 
in comparison with the other groups of rats. Electron microscopical analysis revealed similar findings as 
described after TNF-a alone, although the effects were more prominent at all time points after perfusion. In 
conclusion, our findings suggest that the enhanced anti-tumour effect after the combination of TNF-a with 
melphalan results from potentiation of the TNF-a-induced vascular changes accompanied by increased vascular 
permeability and platelet aggregation. This may result in additive cytotoxicity or inhibition of growth of 
residual tumour cells.
Keywords: tumour necrosis factor alpha; melphalan; isolated limb perfusion; sarcoma; platelets
Isolated limb perfusion (ILP) with TNF-a and melphalan has 
shown impressive results in patients with irresectable soft 
tissue sarcomas and stage III melanoma of the extremities 
(Lienard et al., 1992, 1994). ILP involves isolation of the 
diseased limb, its connection to a heart- lung machine and 
the administration of a triple drug regimen at 39~40°C (mild 
hyperthermia) based on the reported synergism of TNF-a 
with melphalan and interferon-}’ (IFN-y) (Eggermont et al., 
1993). The rationale of ILP is to improve the response rate 
by increasing the drug concentration while avoiding systemic 
toxicity. Morphological and immunohistochemical analysis of 
biopsies from patients after ILP suggested that the tumour 
microvasculature is a major target for TNF-a and melphalan. 
We and others have shown previously that events such as von 
Willebrand factor release, platelet aggregation and congestion 
concentrated on the tumour vasculature, leaving the normal 
tissues largely unaffected (Renard et al., 1994, 1995). 
However, the mechanisms of in vivo synergistic anti-tumour 
effects of TNF-a and melphalan are still not understood
As the drug regimen in patients contains at least two 
experimental drugs, it does not allow us to reach definitive 
conclusions about the relative contribution of TNF-a and
melphalan. an experimental isolated perfusion
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model on sarcoma in the rat was devised. Rats transplanted 
with a non-immunogenic BN sarcoma in the hind leg were 
treated by isolated limb perfusion (Marquet et al., 
Benckhuijsen et al., 1982; Manusama et al., 1994). Using this 
model, we recently showed in vivo synergism between TNF-a 
and melphalan in ILP with a tumour response resembling the 
clinical results (Manusama et al., 1996). ILP in the rat with 
saline or 50 fig of TNF-a alone had no impact on tumour 
growth, and 40 /¿g of melphalan only temporarily inhibited 
tumour growth. In the group perfused with the combination 
of both TNF-a and melphalan, complete regression occurred 
in 75% of the rats. The aim of the present work was to study 
in this rat model the histopathological changes after ILP with 
TNF-a alone, melphalan alone and the combination of both
the pathomechan ism s
light andat
drugs and so shed more 
involved. We
electron-microscopical level that the histopathological 
changes observed in the tumours after perfusion with TNF- 
a alone were augmented by addition of the chemotherapeutic
Materials and methods
Male rats of the inbred BN strain, weighing 250 -300 g, were
The Netherlands). 
(Hope Farms,
obtained from Harlan-CPB 
They were fed a standard laboratory
Woerden, Netherlands) and kept under standard
laboratory conditions. The specific protocol was approved 
by the committee on animal research of The Erasmus 
University, Rotterdam, The Netherlands.
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in Table I. The r recirculated thepump
perfusate at a flow rate of 2.4 ml min which was sufficient 
to maintain the partial pressure of oxygen, (pO:) in the 
was used (Marquet et al., 1983). This BN 175 sarcoma is a tumour (Manusama et al., 1994). A washout was done at the
The spontaneous BN 175 sarcoma transplantable to BN rats
rapidly growing and metastasising tumour. Immunogenicity 
of the tumour was determined by inoculating rats with
end of the perfusion with 2.0 ml of oxygenated Haemaceel. 
The perfusion time was 30 min, including the washout, After
tumour, excising the tumour, reinoculating the rats with the the procedure, the femoral vessels of the perfused limb were
same tumour and measuring the percentage of rats that ligated, which was allowed by restoration of the collateral
show tumour take. According to this method, described by circulation. In the BN rat, the presence of collateral
Prehn and Main (1957), BN 175 sarcoma is non- 
immunogenic.
Isolated limb perfusion (ILP)
The tumour model and perfusion procedure were described
smallpreviously by Manusama et al. (1994, 
fragments of BN 175 sarcoma (3-5  mm) were implanted in 
the right hind limb subcutaneously. Perfusion was performed 
in rats with established tumours with a mean diameter of
13.6 ±3.0 mm at days after10.3 +  3.0
Hypnorm (10 mg ml” 1 fluanisone, 0.315 mg ml
transplantation. 
' ' fentanylci-
trate: Janssen Pharmaceutica, Tilburg, The Netherlands) was 
given i.v. for anaesthesia. A warm water mattress was applied 
around the leg to maintain the temperature of the leg at 38 - 
39"C. The temperature of the leg was measured during the 
perfusion by a naked bead type K probe fixed with its tip at 
the convexity of the tumour and connected to a digital 
thermometer (Mera Benelux, Berkel-Enschot, The Nether­
lands). The femoral artery and vein were approached by a 
parainguinal incision and cannulated in the distal direction 
with silastic tubing (artery: 0.30 mm inner diameter, 0.64 mm 
outer diameter, vein: 0.64 mm inner diameter, 1.19 mm outer 
diameter) (Dow, Corning, MI, USA). Collaterals of the 
femoral vessels were occluded during the perfusion by the 
application of a tourniquet in the groin. The tourniquet was 
fixed at the inguinal ligament. Isolation time commenced 
when the tourniquet was tightened. The circuit included an 
oxygenation chamber (5 ml syringe; Braun 
Germany) and a roller pump (type 505U; Watson Marlow, 
Falmouth, UK). The perfusion was started by circulating 
5 ml of Haemaccel (Behring Pharma, Amsterdam, The 
Netherlands) resulting in a haemoglobin content of approxi­
mately 1 mmol 1~' (mean 0.94 + 0.16). Melphalan (Wellcome, 
London, UK) and TNF-a (recombinant human TNF-a, 
(Boehringer Ingelheim, Germany) were added as boluses to
oxygenation resevoir. The treatment 1%
Table I ation of the treatment modalities
Treatment
Sacrifice
(hours after perfusion) Number o f  rats
. L* k . .b u l> .  II .M  »» ■ -  ,  «A- s*  I... ...............pa i n ~ m t  •• v  n  «  •—T F t  4 b.i^. # • >>> »II».—I » •*»
Controls
(without perfusion)
Saline
0 5
Melphalan (40 fig)
T N F -a  (50ug)
Melphalan and TNF-a 
(40 /xg and 50 fig
respectively)
2
4
12
24
72
2
4
12
24
2
4
12
24
72
2
4
12
24
72
4
5 
1
3
1
3
4 
1 
3
5
6
3 
6 
2
4
6
3
8
3
circulation was demonstrated by a continuous venous return 
when the femoral artery was ligated. Furthermore, oxygen 
pressure in the tumour after ligation of the femoral vessels
was equivale at ore as in a
previous study (Manusama et at., 1994).
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Figure 1 Degree of tumour necrosis after various treatment 
regimens, expressed as percentage of the cross-section.
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The tumours were excised
muscle formed
rim of skin 
resection margin.
the
removal, the tumours were carefully cut in two almost equal
In 42 out of 76 rats one
in liquid nitrogen andof the s
stored at — 80°C until further processing and the other half
marginwas into a
I tissues) and a central part (containing
Paraffin sections of ILP-treated rat BN sarcoma, haematoxylin eosin (HE) stained, (a) Overview of tumour and skin, 
24 h after ILP with saline (magnification x40). (b) Tumour, 24 h after ILP with saline (magnification x 200, detail from a). A blood 
vessel is marked by an arrow and a mitotic figure by an arrowhead, (c) Overview of tumour and skin, 24h after ILP with melphalan
x40). (d) Tumour, 24h after ILP with melphalan (magnification x 200, detail from c). (e) Overview of tumour and 
skin, 2 4 h after ILP with TNF-a (magnification x40). (f) Tumour, 24 h after ILP with TNF-a (magnification x 100, detail from le).
is marked by an arrow, (g) Overview of tumour and skin, 24 h after ILP with the combination o f  TNF-a and 
melphalan (magnification x40). (h) Tumour, 2 4 h after ILP with the combination of TNF-a and melphalan (magnification x 100, 
detail from g). A blood vessel with a thrombus is marked by an arrow, s. Skin; t, tumour; n, necrosis; h, haemorrhage.
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tumour lrom the centre of the lesion) and for were noted in the tumour and at the interlace of tumour with
ultrastructural analysis. In 34 rats, both parts of the specimen dermal and subcutaneous tissues (not shown). Margination of 
were formalin-fixed and embedded in paraffin. Gyrostat and polymorphonuclear cells was apparent in dih
paraffin sections (4 jum) were haematoxylin-eosin stained. 
Tumour necrosis was assessed by conventional histological 
criteria; the percentage of non-viable tumour was estimated
to the tumour (not shown).
Slices of tumours treated with melphalan
in a representative histological section that included both the generally appeared solid and grey. Microscopical examina-
central and the peripheral borders of the tumour bed and tion 24 h after melphalan showed a highly cellular tumour
expressed as percentage of the cross-section and scored in the mass (Figure 2c and d). Over 80% of the cut surface of the
following categories: 0 -20% , 21-50% , 51-80%  and 81 - tumour sections consisted of apparently vital tumour tissue.
100%. The extent and character of the inflammatory infiltrate Interstitial oedema, scattered areas of necrosis and individual
was evaluated. The slides were read by two cell necrosis were observed in the remaining part oí
observers. In case of disagreement, consensus was reached tumour. Necrosis was of the coagulative type. Tumour cells
during joined re-examination.
StOC
Platelet aggregation was visualised by immunohistochemistry 
on representative cryostat sections that included both 
central and the peripheral border of the tumour bed, 4, 12 
and 24 h after perfusion with saline (« = 4), melphalan (/? = 4), 
TNF-a (n — 6) and TNF-a in combination with melphalan 
(n — 6). Cryostat sections (4 ¡xm) were stained using a two- 
step immunoperoxidase procedure, as described previously 
(Nooijen et a l 1996), using MAb PLl-l/E r 21 (Baghus et «/., 
1989) directed against rat platelets, kindly provided by Dr E 
De Heer (University Hospital Leiden, Leiden, The Nether­
lands), and using PAb RaHu FVIII, recognising von 
Willebrand factor (VWF) from the Central Laboratory of 
the Netherlands Red Cross Blood Transfusion Service (CLB). 
As secondary antibodies, peroxidase-conjugated swine anti­
rabbit Ig and rabbit anti-mouse Ig were used (Dako, 1:100), 
preabsorbed with 5% normal rat serum. The peroxidase label 
was visualised by incubation with 3-amino-9-ethylcarbazole 
as a substrate. The semiquantitative grading used was as 
follows: no change (o), sporadic event (± ) , focal event ( + ), 
generalised event ( + +).
Electron microscopy
Small tissue fragments from the central and the peripheral part 
of the tumour were immediately fixed for 24 h in 2.5% 
glutaraldehyde with 0.1 mol sodium cacodylate. The material 
was post-iixed in 1% osmium sodium cacodylate buffer for 1 h 
at room temperature (RT), dehydrated and embedded in epon 
812. One micron sections were cut and stained with toluidine 
blue for light microscopy. Ultrathin sections were cut with a
diamond (Drukker, Cuijk, The on an
ultramicrotome (Reichert Jung, Vienna, Austria). The ultrathin 
sections were contrasted for 15 min with uranyl 3%, followed 
by a 3 min treatment with lead citrate, and examined and 
photographed with a JEOL 1200 EX/II electron microscope 
(Tokyo, Japan) at 60 kV. The electron microscopical analysis 
focused on the microvascular changes.
with fragmented nuclei were encountered, compatible with 
apoptosis. Haemorrhage was virtually absent. The tumour
±
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Results
Histology
The semiquantitative assessment of tumour necrosis in a 
representative histological section after the different treatment 
modalities at various time points following the perfusion is 
shown in Figure 1.
Controls Slices of tumours from and un-
treated control rats showed the presence of solid and grey 
tumour mass between the epidermis and the muscle of the 
right hind limbs. Histology revealed individual cell necrosis 
and scattered areas of confluent necrosis, both of the 
coagulative type. Over 80% of the tumour consisted of 
apparently vital tumour tissue with several mitotic figures and 
showing a high vascularity (Figure 2a and b). Apoptotic 
bodies were seen incidentally. Hyperaemia and oedema were 
observed locally. Scattered mononuclear inflammatory cells
±
0
0
TNF-a and melphalan
•  •  •
•  •
4 12 24
Time after perfusion (h)
Figure 3 Semiquantitative assessment o f  platelet aggregation 
after various treatment regimens, in a representative cryostat 
section. O, No change; ± ,  sporadic event; + , focal event; + + , 
generalised event.
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mass was hardly infiltrated by polymorphonuclear cells, but 
scattered mononuclear inflammatory cells were observed in 
the centre and at the margin.
TNF-% Slices of tumours from animals treated with TNF- 
a generally appeared red and soft in comparison with the
solid tumours in the untreated and saline-treated
controls. Histology of the material harvested 2 h after ILP 
with TNF-a revealed vascular congestion, marked inter­
stitial oedema and focal extravasation of erythrocytes (not 
shown). These vascular effects were most obvious in the 
tumour margins and in the adjacent connective tissue. Four 
hours after ILP, TNF-a induced a red discoloration with
haemorrhage and marked vascular congestion 
(defined as dilated vessels compacted with erythrocytes as 
a sign of hyperaemia and/or haemostasis) compared with 
the controls, both in the central parts of the tumour and at 
the interface of the tumour with dermal tissues (not
shown). Twenty-four hours TNF-a treatment,
haemorrhage and tumour cell necrosis could be observed 
centrally and constituted 20-60%  of the tumour (Figure 2e 
and f). Vascular congestion and thrombi were often seen. 
Histologically vital-appearing tumour cells were situated at 
the margins next to normal skin. In and around areas with 
haemorrhage, scattered mononuclear inflammatory cells 
could be observed. Infiltration of the tumour by poly­
morphonuclear cells was seen in four rats (two rats 4 h 
after ILP and two rats 24 h after ILP) (not shown).
Combination of Slices of tumours
vessels next to the tumour. Al 4 h after perfusion, vascular 
congestion and haemorrhage were generally seen (not 
shown). Twelve hours after ILP these effects were intensified 
with increased disintegration of tumour cells, showing 
apparent nuclear pyknosis or fragmentation. These effects 
were more prominent centrally in the tumour. By 24 h, 
approximately 80-90%  of the tumour had undergone 
extensive necrosis. Cell debris, oedema, haemorrhage, 
thrombi and mononuclear inflammatory cells were observed 
(Figure 2g and h). In three rats (out of 24), a moderate 
infiltration of the tumour by polymorphonuclear cells was 
observed (not shown). In addition, the epidermis overlying 
the area of central necrosis was necrotic (Figure 2g). A rim of
viable tumour cells at the margins next to the
dermis (Figure 2g and h) and seemed to be responsible for 
the outgrowth of the tumour over the subsequent days.
PLl-1 (platelets') The semiquantitative assessment of 
platelet aggregation in a representative histological section
various treatment modalities at various time points 
following perfusion is shown in Figure 3. Sections of the 
saline-treated rats 4, 12 and 24 h after perfusion showed 
sporadic ( ± )  intravascular PL1-1 staining in the tumour 
(Figure 4a). PL 1-1 staining 4, 12 and 24 h after melphalan 
treatment varied from sporadic ( ± )  to focal ( + ) (Figure 4b). 
PL 1-1 staining in the vessels outside the tumour was 
sporadically observed. TNF-a-treated rats showed intravas­
cular PL1-1 staining focally ( + ) in the tumour 4 h  after
from animals treated with the combination of drugs generally treatment (not shown). Generalised (+  + ) PL 1-1 staining was 
appeared red and soft. Microscopic examination 2 h after observed 12 and 24 h after TNF-a-perfusion (Figure 4c).
ILP revealed marked vascular congestion and interstitial PL1-1 staining was also observed in vessels adjacent to the
oedema along with extravasation of erythrocytes (not shown). tumour. Perfusion treatment with TNF-a in combination 
Scattered mononuclear inflammatory cells were present in the with melphalan showed intravascular PLl-1 staining focally
tumour and at the periphery. Margination of polymorpho­
nuclear cells was observed in a few cases in some dermal
( + )  in the tumour in sections 4 h after perfusion (not 
shown). In all sections 12 and 24 h after perfusion with TNF-
Fignre 4 Immunohistochemical staining with the platelet marker PLl-1 on frozen sections of rat BN sarcoma, (a) Overview of 
tumour, 12h after ILP with saline (magnification x 50) showing sporadic ( ± )  PLl-1 staining, (b) Overview of tumour, 12h after 
ILP with melphalan (magnification x 50) showing focal ( + ) PLl-1 staining, (c) Overview of tumour, 12 h after ILP with TNF-a 
(magnification x50) showing generalised (+  + ) PLl-1 staining, (d) Overview of tumour, 12 h after ILP with TNF-a and melphalan 
(magnification x50) showing marked generalised (+  + )  PL 1 -1 staining, c, Tumour centre; p, periphery of the tumour.
Synergistic effects of TNF-a and melphalan
PTGA Nooijen et al
1913
a in combination with melphalan, marked generalised (+  + ) 
PL1-1 staining was observed (Figure 4d), and also in vessels 
adjacent to the tumour (Figure 4e).
rHu FVIII (von Willebrand We found that this
antibody was not suitable for the analysis as possible leakage 
of von Willebrand factor by the endothelium after perfusion 
treatment in our animal model, as the intensity of the 
endothelial staining was low in combination with a diffuse 
background staining.
Electronmicroscopy
The tumours contained numerous small vessels. Intratumoral 
vessels at the periphery of the control tumours and after 
saline perfusion revealed a continuous endothelial cell lining, 
often surrounded by pericytes. Smooth muscle cells were 
only occasionally found. Centrally in the tumour, few 
degenerated endothelial cells were observed in areas with 
oedema and haemorrhage, suggestive of vascular leakage. 
These findings were not accompanied by a marked 
inflammatory cell infiltrate. Platelets were found adherent 
to the vessel wall. The ultrastructural findings after ILP with 
melphalan (40 /¿g) resembled those described after saline 
perfusion.
After perfusion with TNF-a (50 /.¿g), marked intercellular 
oedema was seen. Increased haemorrhage, both centrally 
and at the periphery (2, 4 and 12 h after ILP), suggested 
vascular leakage (Figure 5b). Intratumoral and peritumoral 
vessels showed marked erythrostasis (Figure 5a and 5f). At 
the periphery of the tumours, the vessels loaded with 
erythrocytes revealed signs of endothelial cell degeneration, 
i.e. electron-lucent cytoplasm and swollen mitochondria 
(Figure 5a and c). Extensive aggregation of platelets was 
observed both in the intratumoral vessels and just outside 
the tumour, but merely mural and not occlusive (Figure 5e). 
Increased haemorrhage and intravascular platelet aggrega­
tion were observed 24 h after perfusion with TNF-a in the 
tumour, with disintegration of the endothelial cells (Figure 
5d), only in the tumour centre, with extensive oedema and 
tumour cell necrosis. These phenomena were not accom­
panied by a marked inflammatory cell infiltrate.
Ultrastructural analysis of sections after perfusions with 
TNF-a and melphalan revealed similar findings as described 
after TNF-a alone, although the findings were more prominent 
at all time points after perfusion. Because of this similarity, only 
the ultrastructural changes after TNF-a are shown.
Discussion
Tumour necrosis factor-a (TNF-a) in combination with 
interferon-}1 (IFN-y) and melphalan in an isolated limb 
perfusion setting resulted in a high remission rate in patients
with irresectable soft tissue sarcomas (Lienard et al., 
Eggermont et al., 1992). An overall response rate of 88% 
with a limb salvage of 87% was reported (Eggermont et al., 
1993). However, perfusion with TNF-a alone proved to be 
ineffective (Posner et al., 1994). The mechanism of tumour 
regression by the combination of TNF-a and the 
chemotherapeutic agent melphalan, in vivo, is not precisely 
understood but was proposed to follow a dual targeting 
pathway (Lejeune, 1995; Renard et al., 1995). The first 
target is represented by the tumour microvasculature. TNF-a 
was assumed to induce endothelial cell damage, leading to 
von Willebrand factor release (VWF). Released VWF may
play a role in the adhesion between and the
damaged endothelium or the denuded vessel wall. As a 
consequence, the blood flow is impaired, leading to 
congestion and oedema. The second target is represented 
by the tumour cells themselves, which are increasingly 
subjected to the cytotoxic effects of melphalan in a hypoxic 
environment.
In order to study the impact of the individual drugs on
ILP,
vasation in
Figure 5 Ultrastructural microvascular changes after ILP with 
TNF-a. (a) Blood vessel al the periphery of the tumour, 12 h after
loaded with erythrocytes and lined by degenerated 
endothelial cells (magnification x 4000). (b) Erythrocyte extra­
periphery of the tumour, 4h  after 
(magnification x5000). (c) Detail of the 
Figure 3a, showing signs of degeneration. A swollen 
drion is marked by an arrow (magnification x 6000), (d) Blood
vessel in the tumour centre, 12 h after ILP showing disturbed
of the endothelial
in
mitochon-
by an a r
on x2500). Inset, high power image of part of the 
of the endothelial cell showing merely intact 
mitochondria, (e) Platelet aggregation in a blood vessel in the 
periphery of the tumour, 12 h after ILP (magnification x 
Blood vessel in the dermis adjacent to the tumour, 12h after ILP, 
loaded with erythrocytes. E, erythrocytes; EC, endothelial cell; 
BM, basement membrane; P, platelet.
tumour regression we used an experimental model of sarcoma
in rat. We an in vivo
between two relatively ineffective doses of TNF-a (50 /xg) and 
melphalan (40 (.ig) in this rat model, with a tumour response 
resembling the clinical response (Manusama et al., 1996). The
study was set up to analyse the morphological 
substrate for this synergistic response employing light
microscopic, immunohistochemical and electron microscopic 
methods. Histopathological analysis of the transplanted non-
ILP with TNF-a aloneimmunogenic BN sarcoma 
showed similar findings as reported by Asher et al. (1987) in
g#|psls
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a non-immunogenic MCA-102 murine sarcoma after TNF-a 
i.v. injection and closely resembled the effects described for 
endotoxin-induced histopathological features (van de Wiel et 
al., 1989; Kuper et al., 1985, 1986). TNF-a induced oedema, 
hyperaemia, vascular congestion, extravasation of erythro­
cytes and haemorrhagie necrosis (20-60% ) (Regenass et al.,
1987; MacPherson and North, 1986; Sato et a l 1986).
Remarkably, these events hardly influenced tumour diameter 
and tumour growth in our rat ILP model. Increased doses of tumour effect needs to be analysed in future studies using
associated with vascular congestion and accumulation of 
platelets in areas of vascular damage. Whether polymorpho­
nuclear leucocytes contributed to the vascular damage in our 
rat ILP model is not clear. A polymorphonuclear cell 
infiltrate in the tumour after perfusion with TNF-a and 
with the combination generally was not observed, whereas 
haemorrhage and necrosis were a consistent finding. The 
exact role of polymorphonuclear leucocytes in the anti-
only TNF-a did not lead to an increased anti-tumour effect;
even with of 100 fig in all seven rats, progressive
disease was observed (unpublished results). Furthermore, 
when using TNF-a intravenously in toxic doses, no effect on 
tumour growth was noted in the same model (unpublished
e, the combination with melphalan is 
necessary to obtain an effective anti-tumour response. On
hand, at doses of
occurred with a gradual disappearance of the 
tumour without haemorrhagie necrosis (Manusama et al, 
1996). Combination with TNF-a lowered the effective dose of 
melphalan and introduced a vascular component into 
mechanism of action, characterised by extensive haemor- 
rhagic necrosis.
Oedema and haemorrhage suggested dramatic alterations 
of permeability and integrity of microvascular endothelial 
cells. The cause of the vascular stasis and congestion is not 
clear, but it may be related to a direct cytotoxic effect of 
TNF-a on endothelial cells (Sato et al., 1986). A direct toxic
and activation of procoagulant activity in tumour 
endothelial cells with subsequent thrombus formation might 
be responsible for haemorrhagie necrosis (Gerlach et al., 
1989; Watanabe et al., 1988; Nawroth et al., 1988; 
Shimomura et al., 1988). Using light and electron micro­
scopy, we observed, however, that haemorrhage preceded 
generalised platelet aggregation without fusion of platelets 
with endothelial cells (Grau et al., 1993). Therefore, we 
suggest that the observed platelet aggregation was the result 
of the endothelial damage rather than the initiator. These
are consistent with observed in sequential
biopsies of human lesions after ILP (Renard et al., 1995). In 
most cases, the centre of the tumour seemed to be more 
vulnerable to the treatment than the periphery. Aberrant 
branching and twisting of the vasculature and abnormal high 
pressure in the interstitial matrix of the tumour centre, with 
pre-existing increased vascular permeability, may have led to 
an uneven distribution of the drugs and uneven distribution 
of the vascular changes observed (Jain, 1987«,/?). The vascular 
changes in the tumour margins, accompanied with stasis, may 
have contributed to a decreased blood flow out of the tumour 
with development of central haemorrhagie necrosis.
The anti-tumour activity 1 - 1  n by the
combination of intratumorally injected TNF-a and IFN-y 
syslemically were studied by de Kossodo et al. (1995) in a
breast 
experimental
in anmodel, 
revealed almost similar 
the combination of TNF-a and melphalan. Similar 
potentiation of the anti-tumour activity were observed,
perfusions of granulocytopenic rats. Although it is difficult to 
derive the dynamics of vascular damage and tumour 
regression from static images, our observations support the
interpretation of et al. (1987) that the TNF-a-
induced increase in permeability of the endothelial cells leads
blood viscosity. In this view, the decreasing
impaired by intravascular
to
tumour blood flow is 
platelet aggregation, resulting in a sustained haemostasis and 
finally in haemorrhagie infarction. The increased vascular 
permeability together with a reduced blood flow out of the 
tumour may have led to increased intratumoral concentra­
tions of melphalan or prolongation of its effect. Our findings 
indicate that it is important to measure the effects on vascular 
permeability. Experiments to determine vascular permeability 
changes and melphalan concentrations in the tumours are in 
progress.
Perfusion with the combination of TNF-a and melphalan 
increased both the occurrence and extent of the haemor- 
rhagic necrosis. Necrosis was not confined to the tumour 
cells but also involved microvascular cells, both in the 
tumour and in the adjacent dermis. The potentiation of the 
TNF-a-induced vascular effects by melphalan might be 
explained by additive cytotoxicity direct to the vascular 
endothelium (Regenass et al., 1987; Kachel and Martin, 
1994; Alexander et al., 1987) and/or increased endothelial 
cell reactivity to platelets (Bertomen et al., 1990). Our 
(histo)pathological findings support the proposition by 
Lejeune (1995) that the combination of TNF-a and 
melphalan works through a dual targeting system. In this 
view, the first target is represented by the tumour 
vasculature and the second one by the tumour cells 
themselves. However, proposed granulocyte-mediated
endothelial damage does not seem
non and should be s
sine 
\  In
conclusion, our findings suggest that the enhanced anti­
tumour effect after the combination of TNF-a with 
melphalan results from potentiation of the TNF-a-induced
vascular changes accompanied by increased perme*
This may result in additive cytotoxicity or inhibition of
growth of residual tumour cells.
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